



**Figure 2.** Clonal evolution and *in vivo* treatment resistance of CLL with del(17p13). The counts of white blood cells (white columns) and of clones with distinct aberrations (columns in other colors) as well as therapy are indicated at respective time points. **(A)** Patient No. 59 initially had no aberration and showed acquisition of del(17p13) (black columns) after treatment with chlorambucil although the total number of lymphocytes was reduced after therapy. The del(17p13) clone increased further after treatment with fludarabine. **(B)** Patient No. 60 had del(6q21) and del(13q14) (light and dark grey columns, respectively) at initial analysis and acquired del(17p13) (black columns) without prior treatment. Chemotherapy with chlorambucil resulted in reduction of the clone with del(6q21) and del(13q14) but not of the clone with the additional del(17p13) indicating *in vivo* resistance.